CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRSP Stock’s Performance, Valuation & Estimates Shares of CRISPR Therapeutics have plunged nearly 40% in the past year compared with the industry’s 9% decline, as seen in the chart below.

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside or ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price rise. CRSP/VRTX’s Strong Global Launch Efforts for Casgevy The ...

Cathie Wood’s ARK ETFs capitalized on the pullback in Coinbase (COIN) and Robinhood (HOOD) stocks to load up additional shares on Thursday ...